Indeed, CCL5-deficiency or CCR5 antagonist treatment suppressed tumor growth by reducing the recruitment of immunosuppressive MDSCs and TAMs into the tumor microenvironment in murine breast cancer models [80,81]. Here, CCL5 is linked to breast cancer.